N-methyl-D-aspartate receptors (NMDARs) are ion channels comprising tetrameric assemblies of GluN1 and GluN2 receptor subunits that mediate excitatory neurotransmission in the central nervous system. Of the four different GluN2 subunits, the GluN2D subunit-containing NMDARs have been suggested as a target for antiparkinsonian therapy because of their expression pattern in some of the basal ganglia nuclei that show abnormal firing patterns in the parkinsonian state, specifically the subthalamic nucleus (STN). In this study, we demonstrate that blockade of NMDARs altered spike firing in the STN in a male nonhuman primate that had been rendered parkinsonian by treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In accompanying experiments in male rodents, we found that GluN2D-NMDAR expression in the STN was reduced in acutely or chronically dopamine-depleted animals. Taken together, our data suggest that blockade of NMDARs in the STN may be a viable antiparkinsonian strategy, but that the ultimate success of this approach may be complicated by parkinsonism-associated changes in NMDAR expression in the STN. 
the subthalamic nucleus (STN; Standaert, Testa, Young, & Penney, 1994) . In the STN, NMDARs play an important role in mediating synaptic transmission in the cortico-subthalamic projection, among others (Chu, Atherton, Wokosin, Surmeier, & Bevan, 2015; Swanger et al., 2015) . In individuals with Parkinson disease (PD) and in animal models of parkinsonism, altered activity along this pathway may contribute to firing pattern changes in the STN, specifically the well-described changes of increased firing, increased bursting, and abnormal synchronized oscillatory activity that are typical for the parkinsonian state (Baudrexel et al., 2011; Bergman, Wichmann, Karmon, & DeLong, 1994; Brunenberg et al., 2012; Galvan & Wichmann, 2008; Gatev & Wichmann, 2008; Kita, Nambu, Kaneda, Tachibana, & Takada, 2004; Miller & DeLong, 1987; Nambu, 2005; Rubin, McIntyre, Turner, & Wichmann, 2012; Wichmann & Soares, 2006; Wichmann & Dostrovsky, 2011) .
Our understanding of the potential therapeutic use of NMDARblocking agents in parkinsonism has slowly emerged. Decades ago, administration of broad-spectrum NMDAR antagonists like MK801 was shown to ameliorate some of the motor abnormalities in dopamine-depleted rodents (Allers, Bergstrom, Ghazi, Kreiss, & Walters, 2005; Blandini, Nappi, & Greenamyre, 2001; Greenamyre, 1993; Klockgether & Turski, 1989) , but the use of broad-spectrum NMDAR blockers was considered unlikely to be clinically useful because they would have many severe cognitive and other side effects. Studies have further shown that administration of APV into the STN corrected locomotor activity, burst firing, and cortex-STN synchronization in a 6-OHDA rat model (Pan, 2014) . However, the use of NMDAR subunitselective antagonists remains an attractive strategy to treat PD, based on the possibility that selective blockade of NMDA receptors in the STN, either through local administration of drugs, or through the use of compounds that act at the STN level with some specificity, such as GluN2D antagonists, may have potential as an antiparkinsonian therapy (Hallett & Standaert, 2004) .
To further explore the idea that local blockade of NMDARmediated glutamatergic transmission in the STN may have antiparkinsonian properties, we studied the neuronal effects of local injections of an NMDAR antagonist in the STN of a parkinsonian monkey (supported by in silico modeling of drug diffusion at the local injection sites), and used immunolabeling to determine the expression of GluN2D NMDARs in the STN, the substantia nigra pars compacta (SNc), and the striatum in rodent models of acute or chronic loss of dopamine.
| M E TH ODS

| Nonhuman primate
The primate experiments were performed in accordance with the United States Public Health Service Policy on the Humane Care and Use of Laboratory Animals, including the provisions of the "Guide for the Care and Use of Laboratory Animals" (Garber et al., 2011) , and were approved by the Biosafety Committee and the Animal Care and Use Committee of Emory University. The studies were carried out in a male Rhesus monkey (Macaca mulatta, 4.7 kg, 5 years old). The animal was pair housed with an animal used in other studies, and had ad libitum access to food and water. For the first weeks of the experiment, the monkey was slowly conditioned to being handled by the experimenter and to sit in a primate chair, using positive reinforcement methods (as detailed in McMillan, Perlman, Galvan, Wichmann, & Bloomsmith, 2014) .
The animal was then rendered parkinsonian by weekly administration of small doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, # 41005, Natland International Corp, Morrisville, NC; doses of 0.2-0.6 mg/kg i.m.). The animal was kept in quarantine (with a companion animal) for 72 hr after each injection. The animal received a total of 39.3 mg MPTP (8.2 mg/kg), in 15 individual injections, 0.4 to 0.6 mg/kg each. The total duration of treatment was 19 weeks. After the final MPTP treatment, we waited 8 weeks before recording to let the parkinsonian signs stabilize. To assess the degree and stability of the MPTP-induced motor disability, we scored 10 aspects of motor function (bradykinesia, freezing, extremity posture, trunk posture, action tremor, the frequency of arm and leg movements, finger dexterity, home cage activity, and balance), each on a 0-3 scale, as done in multiple other studies before (Devergnas et al., 2014; Galvan et al., 2016; Kammermeier, Pittard, Hamada, & Wichmann, 2016 were embedded into an acrylic skull "cap," along with a stainless-steel head holder and multiple bone screws. After the surgery, the monkey received analgesics and prophylactic antibiotic treatment for 1 week.
Recordings started after the end of this postprocedural treatment.
| Electrophysiological recordings
The monkey was seated in a primate chair with its head immobilized, leaving body and limbs free to move. Recordings were performed while the monkey was awake, as determined by continued visual observations. We lowered tungsten microelectrodes (FHC, Bowdoinham, ME; Z 5 0.5-1.0 MX at 1 kHz) into the brain with a microdrive (MO-95B; Narishige, Tokyo, Japan). The electrical signals were amplified (DAM-80 amplifier; WPI, Sarasota, FL), filtered (40026000 Hz; Krohn-Hite, Brockton, MA), displayed on a digital oscilloscope (DL1540; Yokogawa, Tokyo, Japan), and made audible via an audio amplifier. The location and borders of the STN were defined based on the single-unit extracellular recordings (Devergnas et al., 2016; Kliem, Pare, Khan, Wichmann, & Smith, 2010; Wichmann & Soares, 2006) and later confirmed by histology (see below).
| Intracerebral injections
The intracerebral microinjections in primates used a custom-built device ("injectrode") consisting of a tungsten microelectrode that was
glued to a thin silica tube (Kliem & Wichmann, 2004) . The tip of the electrode protruded 175 to 200 mm beyond the tip of the silica tubing.
The tubing was connected to a 1-ml gas-tight syringe (CMA Microdialysis, Solna, Sweden) driven by a computer-controlled injection pump (model 102, CMA). The injectrode was lowered into the STN with a microdrive and positioned to record single-neuron activity. Recordings of individual neurons started with a baseline recording period, lasting at least 60 s, followed by recordings during the drug injections (0.5 ml at 0.1-0.2 ml/min) and post injection (up to 10 min). Only one injection was made in each experimental session.
We used injections of D-APV or saline. The drug solution was prepared by dissolving 5 mM APV into sterile saline. The drug injections were done by an investigator blinded to the injected compound, using randomly coded matched tubes of vehicle or APV.
| Termination of primate experiments
To terminate the series of experiments, the monkey was injected with an overdose of sodium pentobarbital (100 mg/kg, i.v.) and then transcardially perfused with cold oxygenated Ringer's solution, followed by a fixative containing 4% paraformaldehyde and 0.1% glutaraldehyde in a phosphate buffer (PB) solution. After perfusion, the brains were removed from the skull, cut coronally into 10-mm-thick blocks, and postfixed overnight in 4% paraformaldehyde. The blocks were then cut into 60-lm-thick coronal sections using a vibrating microtome and stored at 220 8C in an antifreeze solution, containing 30% ethylene glycol and 30% glycerol in PB, until ready for immunohistochemistry. Sections containing the STN were stained for Nissl substance to visualize electrode penetrations, while alternate sections were immunolabeled for the neuronal marker microtubule-associated protein 2 (mouse anti-MAP2; 1:1,000; Millipore, # MAB3418, RRID:AB_94856, Burlington, MA.) to assess the extent of neuronal damage induced by the electrode tracks and to localize the borders of the thalamus. Injectrode tracks were visualized using images of the MAP2-stained sections. Using depth readings obtained during the injectrode recording sessions, individual recording sites were verified to be in the STN.
| Analysis of electrophysiological data
We used offline waveform-matching spike sorting (Spike2; CED, Cambridge, UK) to detect spikes in records of neuronal activity. The spike sorting was performed by an investigator unaware of the injected compound. Principal component analysis and an analysis of the distribution of interspike intervals (ISIs) were used to verify the quality of the spike sorting. All subsequent data analysis steps were carried out in MATLAB (MATLAB version 9.1; Mathworks, Natick, MA), using the ISI information. To analyze the effects of microinjections of saline or APV on the firing rates and pattern of neurons, we compared in each cell a "control" and an "effect" period. The control epoch consisted of the entire (usable) baseline segment of data. The effect period was a segment of postinjection data, starting at least 30 s after the start of the injection.
To determine the onset and offset of the drug effect period, we generated second-by-second readouts of firing rates (based on a sliding 30-s window), which were subsequently smoothed with a 20-point moving averaging technique. The onset and offset of "effects" were defined as the time during which the postinjection firing rate first moved beyond or below the mean 6 2 standard deviations of the baseline period. In case no significant firing rate effect was detected, we used the entire postinjection data window for the analysis.
Several parameters of neuronal firing were calculated in the analysis of the extracted baseline and effect ISI sequences, including the average firing rate (number of spikes[s] within the analyzed segment), the coefficient of variation of the ISIs, the power spectra of neuronal firing, and parameters describing bursts in discharge. The power spectral analysis used the Neurospec 2.0 Matlab functions for frequency domain analyses of neuronal spiking data (Halliday, 2008; Nielsen, Conway, Halliday, Perreault, & Hultborn, 2005) . For each neuron, raw spectra were integrated in the ranges of 1-3 Hz, 3-8 Hz, 8-13 Hz, 13-30 Hz, and 30-100 Hz, and the resultant values expressed as a fraction of the power in the entire 1-to 100-Hz band. Similar methods have been used in our previous publications (Galvan, Hu, Smith, & Wichmann, 2010; Legendy & Salcman, 1985; Wichmann & Soares, 2006) . To detect bursts in firing, we used the method described by Legendy and Salcman (1985;  see also Devergnas et al., 2014; Sanders, Clements, & Wichmann, 2013; Wichmann & Soares, 2006) , with a "surprise" value of 3. We calculated the frequency of occurrence, the mean intraburst firing rate, the proportion of spikes in bursts (compared with the total number of spikes), and the average number of spikes per burst. Comparisons between control and effect periods (for saline and APV) were carried out using paired t tests. 
| Simulation of D-APV diffusion in the STN
Here, C 0 represents the initial concentration of diffusing D-APV injected in the neuropil (5 mM). The apparent diffusion coefficient for
Dfree k 2 50:28 lm 2 =ms ) was calculated using the free diffu- At each time step, a new release event was simulated and added to the previously evoked concentration profile of D-APV. All calculations were performed using custom-made codes written in IgorPro 6.37
(Wavemetrics, Lake Oswego, OR).
| MPTP treatment and DAT immunoreactivity in mice
All procedures using mice were approved by the Institutional Animal 
| Micropunching and NMDAR immunoblotting from mouse tissue
Brains obtained from rapidly decapitated animals (separate from those used for the aforementioned DAT immunoreactivity studies) were quickly removed, and 250-to 300-mm sagittal slices containing the STN, SNc, and striatum were prepared in ice-cold PBS using a vibrating microtome (VT1200S, Leica, Wetzlar, Germany). Tissue discs from the above-mentioned three nuclei were removed using a 0.5-mm tissue punch under a dissecting light microscope (Stoelting, Wood Dale, IL) and frozen immediately on dry ice (Swanger et al., 2015) . The tissue was homogenized in lysis buffer (pH 7.4) containing (in millimolar) 150
NaCl, 50 Tris, 50 NaF, 5 EDTA, 5 EGTA, 1% Triton, 1% SDS, and protease inhibitor cocktail obtained from Sigma Aldrich (P8340) using a
Model CL-18 tissue homogenizer with a setting below 10 for the amplitude to minimize protein degradation (Fisher Scientific). We used 4 mice per group (1 group per treatment, i.e., 21 and 42 days, 1 group per treatment). Animals were randomly selected for assignment to different groups. The investigators were not blinded to these group assignments.
Equal amounts of protein were loaded for each sample quantified Table 1 . Blocking of nonspecific binding at membranes was performed with 5% milk in TTBS for all antibodies except for GluN2B (2% nonfat milk used for blocking and 1% for antibody incubation). To reevaluate the same membrane, they were exposed to Restore Stripping Buffer (Pierce, 21059) for 15 min, washed with PBS, and blocked with 4% milk again before being reblotted with the next primary antibodies. Signals from antibodies were imaged with raw films, using a Bio-Rad Gel Doc Imager. The blots were analyzed using Alpha View immunoblotting analysis software (Bhattacharya et al., 2017) .
| Statistics
For each cell in primate recording, the values for the different descrip- (Figure 1a) . In these simulations, we estimated the apparent diffusion coefficient (D Ã 50:28 lm 2 =ms ) using a value for tortuosity (k 5 1.54) that matched the one measured experimentally in the rat striatum (Rice & Nicholson, 1991) . We first modeled the release of 0.5 ml D-APV (5 mM) at a rate of 0.1 to 0.2 ml/min using a Accordingly, the concentration of D-APV at the recording site varies over 4 orders of magnitude within the first 5 min after the injection. On the basis of these findings, in our recordings, we made sure that our electrophysiology measures were performed consistently 5 min after the end of the D-APV injection (see Figure 2) . We then performed a series of simulations of NMDAR-EPSCs using a kinetic scheme described by Clements & Westbrook (1994) following preequilibration with different D-APV concentrations and instantaneous release of 1 mM glutamate (Figure 1f,g ). The glutamate transient decayed exponentially with a time constant of 1 ms (Clements, 1992 ; Figure 1d ). The EC 50 for block by preequilibrated D-APV was $0.5 mM, similar to the concentration predicted to be reached by the diffusion analysis. 
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The analysis thus indicates that APV blocked > 50% of NMDARs near the recording site within the time period analyzed in this report.
In the in vivo portion of these experiments, we injected vehicle or D-APV into the STN of a parkinsonian monkey while simultaneously recording neuronal spike firing in this nucleus. As shown in Figure 2 , we identified neurons with a stable baseline rate of spontaneous spike firing. We then injected 500 nl of either vehicle or 5 mM D-APV directly into the STN. The results are shown in Table 2 . We found that both the spike firing rate and the intraburst firing rate were significantly reduced. The proportion of spikes in bursts (out of all spikes recorded) and the number of spikes per burst remained the same for both vehicle and D-APV microinjection, suggesting that the cells continued to fire bursts, but that the bursting was less intense after the D-APV injections. D-APV did not alter power spectral measures of oscillatory spiking activity (Table 2) .
Subsequent postmortem analysis of the STN revealed that the locations of all recording electrodes and microinjections were in the STN (Figure 2b ). These data provide the first evidence of a contribution of NMDAR activity to STN spike firing in a nonhuman primate model of parkinsonism.
| Impaired GluN2D expression in STN of MPTP-treated mice
We assessed the loss of striatal dopaminergic terminals in mice treated with MPTP by measuring the DAT immunoreactivity. DAT immunoreactivity has been further shown to strongly correlate with other markers of dopamine terminal integrity, such as dopamine content and tyrosine hydroxylase expression (Caudle et al., 2007) . Mice injected with MPTP (5 daily injections of 20 mg/kg) showed an 80% loss of striatal DAT immunoreactivity 21 days after the final injection ( Figure   3 , left panel, n 5 5, ****p < .0001). Forty-two days after completing the MPTP injection protocol, the animals showed a 55% loss of striatal DAT (Figure 3 , right panel, n 5 5, **p 5 .005). A 2-tailed t test was performed to establish statistical significance in these experiments.
Murine STN neurons express the GluN1, GluN2A, GluN2B, and GluN2D subunits of NMDARs, which likely combine to form triheteromeric NMDARs, and their altered structure is involved in disease states (Standaert et al., 1994; Swanger et al., 2015) . GluN2D-containing NMDARs mediate synaptic transmission and control spike firing in the STN. Hence, we wanted to examine GluN2D protein expression in the parkinsonian state (Swanger et al., 2015 (Swanger et al., , 2017 . To investigate whether MPTP-treated mice showed altered GluN2D subtype expression, we quantified GluN2D protein expression in tissue micropunches, using
Western blots. We found that GluN2D immunoreactivity was significantly reduced in the STN both 21 days and 42 days after the MPTP injections compared with their age-matched controls (Figure 4a-c; n 5 4 animals per group; *p < .05, **p < .01; 2-tailed t test, each sample replicated 2 times). GluN2D expression was also reduced 42 days post MPTP injections in the SNc and the striatum, but not in the 21 days age group, suggesting a gradual progression of the effect of MPTP on GluN2D expression in adjoining areas of the brain in our MPTP model. 
| D ISC USSION
NMDARs are potentially important CNS targets for the treatment of neurological and psychiatric disorders (Zhou & Sheng, 2013) Number of spikes per burst 1.12 6 0.21 1.00 6 0.04 .623
Intraburst firing rate 0.66 6 0.05 1.10 6 0.07 < .001
Data are presented as mean 6 SEM of postinjection values, normalized to the preinjection baseline of the respective cells. The significance was assessed using independent-sample t tests, comparing the ratios obtained with D-APV versus those obtained with saline injections.
FIG URE 3 Analysis of dopamine transporter (DAT) expression in the mouse striatum following 5 daily injections of MPTP (20 mg/kg), 21 (left) and 42 days post injection (right). The insets are representative Western blots demonstrating the reduction of DAT immunoreactivity (M 5 MPTP-treated sample; S 5 saline; numbers correspond to different samples, S1-5 and M1-5 were control and MPTP treated animals at 21 days after injection respectively, and S6-10 and M6-10 were control and MPTP treated animals at 42 days after injection respectively. n 5 5 independent experiments, ****p < .0001 for 21 days post lesion and n 5 5, **p 5 .005 for 42 days post lesion, 2-tailed t test)
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| 1331 Zhang, Feng, & Chergui, 2014b) . While GluN2D receptors are expressed in parts of the brain outside of the basal ganglia and related structures, high levels of these receptors exist in several basal ganglia structures in the adult brain, including the globus pallidus, substantia nigra, and, prominently, the STN (Clarke & Bolam, 1998; Hamani, Saint-Cyr, Fraser, Kaplitt, & Lozano, 2004; Monyer, Burnashev, Laurie, Sakmann, & Seeburg, 1994; Standaert et al., 1994; Swanger et al., 2015; Wenzel, Villa, Mohler, & Benke, 1996; Wilson & Bevan, 2011) . GluN2D subunit expression in these nuclei suggests that these receptors could be a useful pharmacologic target for the treatment of parkinsonism.
While parkinsonism results from the loss of the dopaminergic nigrostriatal tract, the pathophysiology of PD includes secondary changes in GABAergic and glutamatergic transmission throughout the basal ganglia (Carlsson & Carlsson, 1990; DeLong, 1990; Fearnley & Lees, 1991; Kish, Shannak, & Hornykiewicz, 1988; Obeso et al., 2000) . which may contribute to increased firing, increased burst firing, and the development of alpha-and beta-band oscillations in firing in the STN, which are typical for the parkinsonian state (Galvan & Wichmann, 2008; Pan et al., 2014 Pan et al., , 2016 .
Our study of the effects of NMDA receptor blockade was limited in that only one animal was studied, and only a single dose of the NMDA receptor blocker D-APV could be used. However, even given these limitations, we were able to show that NMDAR blockade with D-APV significantly reduced spike firing rate and the intensity of burst firing (as judged by the maximal number of spikes in bursts), although it did not affect the overall prevalence of bursts. Importantly, the D-APV dose and the timing of recording relative to the drug injections were clearly adequate to assess the effects of blocking NMDARs in the STN, as demonstrated through our drug diffusion simulations. Both the effects on firing rates and on bursting would counteract important components of the pathophysiology of parkinsonism (i.e., increased spiking activity and increased bursting in the STN), but it is worth pointing out that we studied this animal only in the parkinsonian state. ) mouse brain tissue sample compared with wild type (Wt). (b,c) Quantification of data from n 5 4 animals evaluated in independent experiments, samples repeated 1 to 2 times per animal. Shown are the GluN2D expression for each animal as means of replicates, GluN2B expression for each sample tested once, with the intensity normalized to tubulin as loading control. *p < .05, **p < .01 compared with age-matched controls; 2-tailed t test It is therefore not possible to say with certainty that the drug infusions "normalized" STN firing in this particular animal. Studies in rodent models have previously shown the positive effects of APV in ameliorating parkinsonian symptoms (Pan et al., 2014) . Taken together, these data are the first evidence of NMDAR control of spike firing in a nonhuman primate model of PD.
Our previous study emphasized the importance of glutamatergic transmission at GluN2D-containing NMDA receptors for STN function (Swanger et al., 2015) , suggesting that GluN2D-containing NMDARs would be an attractive target for the development of novel pharmacological tools for therapeutic approaches in PD (Hallett & Standaert, 2004) . Our experiments profiling NMDAR expression in the basal ganglia provide further insight in this regard. We found in both short-and long-term mouse models of dopamine depletion (21 and 42 days after the end of MPTP treatment) that the expression of GluN2D subunits was reduced in the STN, and that GluN2D expression in the SNc and striatum was significantly reduced in the chronic exposure paradigm (age 42 days after injection). Other studies using 6-OHDA model showed increased GluN2D expression in the striatum (Zhang & Chergui, 2015) . However, the differences in results might be due to the use of different models. We also investigated changes in GluN2B subunit expression in the same regions and found that there were no significant changes across different nuclei. Data from our rodent MPTP model are congruent with our electrophysiological observations from our primate experiment. In our primate MPTP model, we observed rescue of spike firing activity after NMDAR blockade with D-APV. Matching this observation, we expectedly found that expression of at least one subunit (GluN2D) was impaired, while the other subunit (GluN2B) was unaltered, increasing the contribution of GluN2B-containing NMDARs. This finding suggests that an altered ratio of GluN2D to GluN2B might be an important change associated with loss of dopaminergic neurons. Our current data are consistent with our previous study showing that the glutamatergic corticosubthalamic innervation of the STN was substantially reduced in MPTP-treated parkinsonian animals (Chu et al., 2017; Mathai et al., 2015; Pan et al., 2014; Sanders & Jaeger, 2016; Sanders, 2017; Wang et al., 2018) , perhaps as a component of a more general glutamatergic disconnection of the basal ganglia (the cortico-and thalamostriatal innervation also fail in this disease; Villalba, Villalba & Smith, 2017) . Thus, while blockade of glutamatergic transmission in the STN (e.g., through the use of 
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